Company Profile

Apath LLC
Profile last edited on: 6/15/21      CAGE: 38WL3      UEI:

Business Identifier: Treatment of viral infection
Year Founded
1997
First Award
1999
Latest Award
2007
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

760 Parkside Avenue
Brooklyn, NY 11226
   (347) 533-4831
   generalinformation@apath.com
   www.apath.com
Location: Multiple
Congr. District: 09
County: Kings

Public Profile

Apath, LLC is a pharmaceutical discovery and development company with a focus on hepatitis C virus (HCV) and other human viral pathogens. The firm is engaged in the commercial application of virology and viral genetics to discover and develop a range of novel therapeutic products for the treatment of viral infections. Apath’s primary focus is on RNA viruses. RNA viruses account for the majority of viruses which are human pathogens. In addition to HCV, they include several medically important viruses – Influenza, Respiratory Syncytial Virus (RSV), and Hemorrhagic Fever Viruses. The firm successfully licensed their key hepatitis C virus patents to several diagnostic and pharmaceutical compan

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
20-24
Revenue Range
2M-2.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2007 1 NIH $100,713
Project Title: The in vitro hepatitis C virus infection system as a drug discovery tool
2006 2 NIH $687,924
Project Title: Transgenic indicator cells for influenza virus
2005 2 NIH $958,581
Project Title: Replicon-based screening for inhibitors of alphaviruses
2005 2 NIH $741,038
Project Title: Molecular tools for Bunyavirus antiviral screening
2005 2 CBD $849,925
Project Title: Filovirus drug discovery using novel combinations of approved drugs

Key People / Management

  L Janet Milton -- President

  Jack Nightingale -- Former President

  Amine Osman Noueiry

  Charles M Rice -- Founder and Managing Director

  Robert M Roth -- Vice President, Strategic Operations

Company News

There are no news available.